Home/Bryn Pharma/Richard Lowenthal

RL

Richard Lowenthal

Co-founder

Therapeutic Areas

Allergy & Immunology

Bryn Pharma Pipeline

Drug	Indication	Phase
UTULY™	Treatment of severe allergic reactions (Type I), including anaphylaxis	Phase 3

Leadership Team at Bryn Pharma

David Dworaczyk, Ph.D.

Co-founder, President & CEO

View full Bryn Pharma profile